Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas1, Igor Puzanov2, Reinhard Dummer3, Dirk Schadendorf4, Omid Hamid5, Caroline Robert6, F Stephen Hodi7, Jacob Schachter8, Anna C Pavlick9, Karl D Lewis10, Lee D Cranmer11, Christian U Blank12, Steven J O'Day13, Paolo A Ascierto14, April K S Salama15, Kim A Margolin16, Carmen Loquai17, Thomas K Eigentler18, Tara C Gangadhar19, Matteo S Carlino20
1University of California Los Angeles, Los Angeles, CA, USA
2Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
3University of Zürich, Zürich, Switzerland
4University Hospital Essen, Essen, Germany
5The Angeles Clinic and Research Institute, Los Angeles, CA, USA
6Gustave Roussy and Paris-Sud University, Villejuif, France
7Dana-Farber Cancer Institute, Boston, MA, USA
8Sheba Medical Center, Tel Hashomer, Israel
9New York University Cancer Institute, New York, NY, USA
10University of Colorado Denver, Aurora, CO, USA
11University of Arizona Cancer Center, Tucson, AZ, USA
12Netherlands Cancer Institute, Amsterdam, Netherlands
13Beverly Hills Cancer Center, Beverly Hills, CA, USA
14Istituto Nazionale Tumori ‘Fondazione G. Pascale’, Napoli, Italy
15Duke Cancer Institute, Durham, NC, USA.
16Seattle Cancer Care Alliance/University of Washington, Seattle, WA, USA
17University Medical Center, Mainz, Germany
18Universitätsklinikum Tübingen, Tübingen, Germany
19Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA
20Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, and Melanoma Institute Australia, Westmead, NSW, Australia
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
The Lancet Oncology
Tập 16
908-918
Thông tin tác giả